Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,551,815 papers from all fields of science
Search
Sign In
Create Free Account
ophiocordin
Known as:
Benzoic acid, 4-(2-(((hexahydro-4-((4-hydroxybenzoyl)oxy)-1H-azepin-3-yl)amino)carbonyl)-6-hydroxybenzoyl)-3,5-dihydroxy-
, balanol
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Antibiotics, Antifungal
Azepines
Hydroxybenzoates
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Stereoselective synthesis of hydroxylated 3-aminoazepanes using a multi-bond forming, three-step tandem process.
Sajjad Ahmad
,
A. Sutherland
Organic and biomolecular chemistry
2012
Corpus ID: 37874041
A multi-bond forming, three-step tandem process involving a palladium(II)-catalysed Overman rearrangement and a ring closing…
Expand
2010
2010
Recent chemoenzymatic total syntheses of natural and unnatural products: Codeine, balanol, pancratistatin, and oseltamivir
T. Hudlický
2010
Corpus ID: 96945305
Presented here is a short summary of the recent accomplishments in total synthesis in our laboratories. In particular, recent…
Expand
Review
2008
Review
2008
The Protein kinase inhibitor balanol: structure-activity relationships and structure-based computational studies.
V. Pande
,
M. Ramos
,
F. Gago
Anti-Cancer Agents in Medicinal Chemistry
2008
Corpus ID: 31244020
Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA…
Expand
2004
2004
Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3',5'-adenosine monophosphate-dependent protein kinase catalytic subunit.
P. Akamine
,
Madhusudan
,
+4 authors
Susan S. Taylor
Biochemistry
2004
Corpus ID: 26164568
The protein kinase family is a prime target for therapeutic agents, since unregulated protein kinase activities are linked to…
Expand
2002
2002
Synthesis and protein kinase inhibitory activity of balanol analogues with modified benzophenone subunits.
J. Lampe
,
C. K. Biggers
,
+20 authors
Mark L. Stamper
Journal of Medicinal Chemistry
2002
Corpus ID: 24647234
A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits…
Expand
Review
2002
Review
2002
Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis.
Christine M. Gould
,
Chung F. Wong
Pharmacology and Therapeutics
2002
Corpus ID: 24519464
2000
2000
Synthesis of the benzophenone fragment of balanol via an intramolecular cyclization event.
M. Denieul
,
B. Laursen
,
R. Hazell
,
T. Skrydstrup
Journal of Organic Chemistry
2000
Corpus ID: 36758975
Studies are reported on the use of either a 7-exo radical cyclization or an intramolecular Heck reaction as the key step for the…
Expand
1999
1999
Asymmetric synthesis of the balanol heterocycle via a palladium-mediated epimerization and olefin metathesis.
G. Cook
,
P. Shanker
,
S. Peterson
Organic Letters
1999
Corpus ID: 40121423
[formula: see text] The enantioselective formal synthesis of balanol, a potent protein kinase C inhibitor, was accomplished from…
Expand
1997
1997
Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.
Yen-Shi Lai
,
José S. Mendoza
,
+8 authors
L. M. Ballas
Journal of Medicinal Chemistry
1997
Corpus ID: 40737883
Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide…
Expand
1997
1997
Synthesis and protein kinase C inhibitory activities of balanol analogues with modification of 4-hydroxybenzamido moiety.
H. Hu
,
J. Mendoza
,
C. Lowden
,
L. M. Ballas
,
W. Janzen
Bioorganic & Medicinal Chemistry
1997
Corpus ID: 665483
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE